Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility.

ABSTRACT:

Background and objectives

Mesenchymal stromal cells (MSCs) abrogate alloimmune response in vitro, suggesting a novel cell-based approach in transplantation. Moving this concept toward clinical application in organ transplantation should be critically assessed.

Design, setting, participants & measurements

A safety and clinical feasibility study (ClinicalTrials.gov, NCT00752479) of autologous MSC infusion was conducted in two recipients of kidneys from living-related donors. Patients were given T cell-depleting induction therapy and maintenance immunosuppression with cyclosporine and mycophenolate mofetil. On day 7 posttransplant, MSCs were administered intravenously. Clinical and immunomonitoring of MSC-treated patients was performed up to day 360 postsurgery.

Results

SUBMITTER: Perico N 

PROVIDER: S-EPMC3052234 | biostudies-literature | 2011 Feb

REPOSITORIES: biostudies-literature